Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072260 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| SCHEMBL2957367 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| SCHEMBL2957366 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| SCHEMBL2010668 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| SCHEMBL14505292 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4E | |
| Bromide SCHEMBL3419252 | 0.83 | ADRB2 (0.69) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| Bromide SCHEMBL3419254 | 0.83 | ADRB2 (0.69) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| Bromide SCHEMBL5670599 | 0.83 | ADRB2 (0.69) | ADRB2ADRB1ADRB3KDM4EL3MBTL1 | |
| SCHEMBL14030664 | 0.81 | ADRB2 (0.84) | ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL13596180 | 0.81 | ADRB2 (0.48) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885ADRB3 3/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.